1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.23
D/E ratio 1.1-1.25x Drug Manufacturers - Specialty & Generic median of 0.18. Walter Schloss would demand higher asset quality to justify above-average leverage.
0.86
Net debt aligned with Drug Manufacturers - Specialty & Generic median of 0.86. David Dodd would verify if industry standard leverage is appropriate given business cyclicality.
-5.48
Negative coverage while Drug Manufacturers - Specialty & Generic median is 0.00. Seth Klarman would scrutinize operating performance and look for turnaround catalysts.
5.30
Current ratio exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.57. Joel Greenblatt would verify if this conservative approach provides competitive advantages.
39.26%
Intangibles exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 9.55%. Michael Burry would check for aggressive accounting and hidden risks.
